Cytotoxicity of Sorafenib in Human Hepatocellular Carcinoma Cells

Al-Azhar Journal of Pharmaceutical Sciences
doi 10.21608/ajps.2015.12490
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Egypts Presidential Specialized Council for Education and Scientific Research

Related search

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

Synergistic Effects of Ascorbate and Sorafenib in Hepatocellular Carcinoma: New Insights Into Ascorbate Cytotoxicity

Free Radical Biology and Medicine
BiochemistryPhysiology
2016English

In Vivo Inhibitory Effect of Suberoylanilide Hydroxamic Acid Combined With Sorafenib on Human Hepatocellular Carcinoma Cells

Brazilian Journal of Pharmaceutical Sciences
ToxicologyPharmaceuticsPharmacology
2020English

Triclosan Treatment Decreased the Antitumor Effect of Sorafenib on Hepatocellular Carcinoma Cells

OncoTargets and Therapy
OncologyPharmacology
2018English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

A miR-7/GAS6/TYRO3 Axis Regulates the Growth and Invasiveness of Sorafenib-Resistant Cells in Human Hepatocellular Carcinoma

Hepatology
MedicineHepatology
2017English

TGFβ Signaling Confers Sorafenib Resistance via Induction of Multiple RTKs in Hepatocellular Carcinoma Cells

Molecular Carcinogenesis
Cancer ResearchMolecular Biology
2016English

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis

Journal of Hepatology
Hepatology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy